治疗晚期或复发性子宫内膜癌的免疫疗法。

IF 1.1 Q4 ONCOLOGY

Clinical Advances in Hematology & Oncology Pub Date : 2024-04-01

Juan Francisco Grau-Bejar, Lorena Farinas-Madrid, Carmen García-Duran, David García-Illescas, Roberta Mazzeo, Ana Oaknin

{"title":"治疗晚期或复发性子宫内膜癌的免疫疗法。","authors":"Juan Francisco Grau-Bejar, Lorena Farinas-Madrid, Carmen García-Duran, David García-Illescas, Roberta Mazzeo, Ana Oaknin","doi":"","DOIUrl":null,"url":null,"abstract":"The standard treatment of patients with advanced or recurrent endometrial cancer has not significantly changed over the past few decades, reflecting a major unmet clinical need. Fortunately, the arrival of immune checkpoint inhibition is rapidly changing this dismal scenario. This review discusses the most recent results from clinical trials evaluating the use of immune checkpoint inhibitors, either as monotherapy or in combination therapy, in both the post-platinum and frontline settings. Additionally, a section is devoted to the future clinical development of immune checkpoint inhibitors in advanced or recurrent endometrial cancer.","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Immunotherapy in the treatment of advanced or recurrent endometrial cancer.\",\"authors\":\"Juan Francisco Grau-Bejar, Lorena Farinas-Madrid, Carmen García-Duran, David García-Illescas, Roberta Mazzeo, Ana Oaknin\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The standard treatment of patients with advanced or recurrent endometrial cancer has not significantly changed over the past few decades, reflecting a major unmet clinical need. Fortunately, the arrival of immune checkpoint inhibition is rapidly changing this dismal scenario. This review discusses the most recent results from clinical trials evaluating the use of immune checkpoint inhibitors, either as monotherapy or in combination therapy, in both the post-platinum and frontline settings. Additionally, a section is devoted to the future clinical development of immune checkpoint inhibitors in advanced or recurrent endometrial cancer.\",\"PeriodicalId\":51585,\"journal\":{\"name\":\"Clinical Advances in Hematology & Oncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2024-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Advances in Hematology & Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Advances in Hematology & Oncology","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

过去几十年来，晚期或复发性子宫内膜癌患者的标准治疗方法一直没有明显改变，这反映出临床需求仍未得到满足。幸运的是，免疫检查点抑制剂的出现正在迅速改变这一令人沮丧的局面。本综述讨论了评估免疫检查点抑制剂在铂后治疗和一线治疗中作为单药或联合疗法使用的临床试验的最新结果。此外，还有一部分内容专门讨论了免疫检查点抑制剂在晚期或复发性子宫内膜癌中的未来临床发展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

本刊更多论文

Immunotherapy in the treatment of advanced or recurrent endometrial cancer.

The standard treatment of patients with advanced or recurrent endometrial cancer has not significantly changed over the past few decades, reflecting a major unmet clinical need. Fortunately, the arrival of immune checkpoint inhibition is rapidly changing this dismal scenario. This review discusses the most recent results from clinical trials evaluating the use of immune checkpoint inhibitors, either as monotherapy or in combination therapy, in both the post-platinum and frontline settings. Additionally, a section is devoted to the future clinical development of immune checkpoint inhibitors in advanced or recurrent endometrial cancer.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical Advances in Hematology & Oncology ONCOLOGY-

CiteScore

1.10

自引率

0.00%

发文量

期刊介绍： Clinical Advances in Hematology & Oncology (CAH&O) is a monthly peer-reviewed journal reaching more than 27,000 hematology and oncology clinicians. CAH&O provides editorial content encompassing a wide array of topics relevant and useful to the fields of oncology and hematology, both separately and together. Content is directed by the strong input of today’s top thought leaders in hematology & oncology, including feature-length review articles, monthly columns consisting of engaging interviews with experts on current issues in solid tumor oncology, hematologic malignancies, hematologic disorders, drug development, and clinical case studies with expert commentary. CAH&O also publishes industry-supported meeting highlights, clinical roundtable monographs, and clinical review supplements.